Hyaluronic acid grafted bursin polymer as well as preparation method and application thereof

Hyaluronic acid-branched cystin tripeptide polymers were prepared by amidation linking hyaluronic acid and cystin tripeptide, which solved the problem of low efficiency of veterinary vaccine immune enhancers in the prior art and achieved a highly efficient immune enhancement effect.

CN118909036APending Publication Date: 2024-11-08JIANGSU ACAD OF AGRI SCI
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410926705.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Current technology lacks highly effective veterinary vaccine immune enhancers, and the immune-enhancing effect of cystin tripeptide is not significant when used in vaccines.

Method used

Hyaluronic acid is linked to cystin tripeptide via amide bonds to form a hyaluronic acid-branched cystin tripeptide polymer. The carboxyl and amino groups undergo amidation reaction under the action of EDC/NHS. The preparation method is simple and low cost.

Benefits of technology

Hyaluronic acid-branched cystin tripeptide polymer can efficiently enter the inguinal lymph nodes, promote TFH cell differentiation, assist B cells in secreting high levels of antibodies, and significantly enhance the immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909036A_ABST
    Figure CN118909036A_ABST
Patent Text Reader

Abstract

The invention provides a hyaluronic acid grafted bursin tripeptide polymer as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The hyaluronic acid grafted bursin tripeptide polymer is formed by grafting bursin tripeptide to hyaluronic acid through an amido bond. The invention also provides a preparation method of the hyaluronic acid grafted bursin tripeptide polymer, which comprises the following steps: (1) carrying out reaction on hyaluronic acid and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide under a stirring condition; (2) adding N-hydroxysuccinimide into the solution obtained after the reaction in the step (1), and reacting under a stirring condition; and (3) adding bursin into the solution obtained after the reaction in the step (2), and reacting under a stirring condition to obtain the hyaluronic acid grafted bursin polymer. The hyaluronic acid grafted bursin polymer is simple in preparation method, can be used as a veterinary vaccine immunopotentiator, and can induce immune animals to secrete high-level antibodies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a hyaluronic acid-grafted cystin tripeptide polymer and a preparation method and application thereof. Background Art

[0002] Bursin tripeptide is a tripeptide (Lys-His-Gly-NH2) derived from the bursa of birds. Studies have shown that it not only has an immune-enhancing effect on poultry, but also can improve the humoral and cellular immunity levels of mammals. However, when bursin tripeptide is used in vaccines, the immune-enhancing effect is not satisfactory.

[0003] Hyaluronic acid, structure Figure 1 It is a negatively charged natural linear polysaccharide composed of glucuronic acid and N-acetyl-D-glucosamine disaccharides repeatedly connected by β (1, 4) glycosidic bonds. Hyaluronic acid has the advantages of being non-toxic, non-immunogenic, biodegradable, biocompatible, and modifiable. It is rich in functional groups such as carboxyl and hydroxyl groups that can be chemically modified.

[0004] The existing technology lacks highly effective veterinary vaccine immunopotentiators. Summary of the invention

[0005] Based on the above problems, the purpose of the present invention is to provide a hyaluronic acid-grafted cystin tripeptide polymer, which can be used as an immunopotentiator for veterinary vaccines and can induce immune animals to secrete high levels of antibodies.

[0006] Another object of the present invention is to provide a method for preparing the hyaluronic acid-grafted cystin tripeptide polymer, which is simple and low in cost.

[0007] Another object of the present invention is to provide a hyaluronic acid-grafted cystin tripeptide polymer for use as an immunopotentiator in veterinary inactivated vaccines, which can induce immune animals to secrete high levels of antibodies.

[0008] The purpose of the present invention is achieved by the following technical solutions:

[0009] The invention discloses a hyaluronic acid grafted bursa-tripeptide polymer, which is formed by connecting hyaluronic acid and bursa-tripeptide through an amide bond.

[0010] The present invention also provides a method for preparing the hyaluronic acid-grafted cystin tripeptide polymer, comprising the following steps:

[0011] (1) reacting hyaluronic acid and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide under stirring;

[0012] (2) adding N-hydroxysuccinimide to the solution obtained after the reaction in step (1), and reacting under stirring;

[0013] (3) Adding the bursa-tripeptide to the solution obtained after the reaction in step (2), and reacting under stirring conditions to obtain a hyaluronic acid-grafted bursa-tripeptide polymer.

[0014] In the present invention, in step (1), hyaluronic acid is dissolved in an aqueous solvent, and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide is added to react; the aqueous solvent is a buffer solution with a pH of 5.5-7; and the mass percentage concentration of hyaluronic acid in the aqueous solvent is 0.01% to 10%.

[0015] In the present invention, the average molecular weight of hyaluronic acid is 20-200 kDa, preferably 40-60 kDa.

[0016] In the present invention, in step (1), the molar ratio of the carboxyl group in the hyaluronic acid to 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide is 1:1-10, preferably 1:3-5; and the reaction time is 15 min-6 h, preferably 1-3 h.

[0017] In the present invention, the molar ratio of the carboxyl group in hyaluronic acid to N-hydroxysuccinimide is 1:1-10, preferably 1:4-7; the reaction time in step (2) is 1-24 hours, preferably 2-18 hours.

[0018] In the present invention, the molar ratio of the carboxyl group in hyaluronic acid to the thiourea tripeptide is 1:0.1 to 1:8, preferably 1:0.3-2; the reaction in step (3) is carried out in a buffer solution with a pH of 5 to 10, preferably a pH of 7 to 7.5; the reaction time in step (3) is 12 to 48 hours, preferably 14 to 18 hours.

[0019] In the present invention, after the reaction in step (3) is completed, dialysis, concentration and freeze-drying are performed.

[0020] The present invention also provides the use of the hyaluronic acid-grafted cystin tripeptide polymer as a vaccine enhancer.

[0021] In the present invention, the hyaluronic acid-grafted cystin tripeptide polymer is dissolved in an antigen solution, and then mixed with 1313 adjuvant at a volume ratio of 1:0.8-1.2, and emulsified to obtain an inactivated vaccine.

[0022] The beneficial effects of the present invention compared with the prior art are as follows: the present invention uses high polymer hyaluronic acid to chemically modify the bursin tripeptide, and under the action of EDC / NHS, the carboxyl group of hyaluronic acid and the amino group of the bursin tripeptide undergo amidation reaction to form a hyaluronic acid grafted bursin tripeptide polymer, and the preparation method is simple, efficient and low in cost. The hyaluronic acid grafted bursin tripeptide polymer can more efficiently enter the inguinal lymph nodes, promote the differentiation of TFH cells, assist in the screening of B cells that secrete high-affinity immunoglobulins, and induce them to transform into plasma cells to secrete high-level antibodies. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 Schematic diagram of the structure of hyaluronic acid.

[0024] Figure 2 This is the Fourier transform infrared spectrum of HA@NS, where NS is bursa-tripeptide, HA is hyaluronic acid, and HA@NS is a hyaluronic acid-grafted bursa-tripeptide polymer.

[0025] Figure 3 It is the UV wavelength-absorbance relationship diagram of hyaluronic acid, cysteine ​​tripeptide, and the mixture of hyaluronic acid and cysteine ​​tripeptide, wherein Mix is ​​a mixture of hyaluronic acid and cysteine ​​tripeptide, NS is cysteine ​​tripeptide, and HA is hyaluronic acid.

[0026] Figure 4 It is the concentration-absorbance standard curve of bursin tripeptide at a wavelength of 230nm, with the horizontal axis being the concentration of bursin tripeptide and the vertical axis being the absorbance.

[0027] Figure 5 This is the neutralizing antibody level of each vaccine 28 days after immunization.

[0028] Figure 6 HA@NS was used as an immune enhancer and combined with PEDV vaccine. The differentiation levels of TFH cells and GC B cells in the inguinal lymph nodes of mice 14 days after subcutaneous immunization, where HA@NS was prepared in Example 6. The vertical axes were TFH and CD4 + T cell ratio, GC B cell to total B cell ratio. ﹡﹡﹡ indicates a significant difference compared with mice immunized with vaccine C2, p < 0.001. DETAILED DESCRIPTION

[0029] The present invention is further described in detail below in conjunction with the examples and drawings, but the embodiments of the present invention are not limited thereto. The experimental methods in the following examples where specific conditions are not specified are usually carried out under conventional conditions. The raw materials and reagents used in the following examples, unless otherwise specified, can be obtained from commercial sources.

[0030] The MES buffer used in the present invention has a pH of 6.0 and is an aqueous solution containing 0.1 M MES and 0.5 M NaCl. MES is 2-(N-morpholino)ethanesulfonic acid.

[0031] Example 1

[0032] (1) Weigh 0.1 g of sodium hyaluronate with an average molecular weight of 48 kDa (Shanghai Yuanye Biotechnology Co., Ltd., CAS 9067-32-7), add it to 10 mL of MES buffer, and stir at 500 r / min until dissolved to obtain a hyaluronic acid solution.

[0033] (2) Weigh 0.144 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), dissolve it in 500 μL of MES buffer, and then add it to the hyaluronic acid solution obtained in step (1) under stirring. After the addition is completed, react under stirring at 1000 r / min for 1 h.

[0034] (3) Weigh 0.129 g of N-hydroxysuccinimide (NHS), dissolve it in 500 μL of MES buffer, and then add it to the solution obtained after the reaction in step (2) under stirring. After the addition is completed, react under stirring at 1000 r / min for 2 h.

[0035] (4) The pH value of the solution obtained after the reaction in step (3) was adjusted to 7.0 using a 0.05M NaOH aqueous solution. 0.085g of bursa tripeptide (Lys-His-Gly-NH2) was weighed and dissolved in 0.5mL of PBS buffer (concentration of 0.01mol / L) with a pH of 7.2, and then added to the solution obtained after the reaction in step (3) with the pH adjusted, and reacted for 16h. After the reaction, the reaction solution was dialyzed using a dialysis membrane with a molecular weight cutoff of 8000kDa, concentrated using PEG 20000, and the retentate was freeze-dried to obtain a hyaluronic acid-grafted bursa tripeptide polymer, which was recorded as HA@NS.

[0036] The above reaction is carried out at room temperature (15 degrees-40 degrees).

[0037] Example 2

[0038] HA@NS was prepared according to the method of Example 1, except that the reaction time in step (2) was 2 h; the reaction time in step (3) was 5 h; and the amount of bursin tripeptide used in step (4) was 0.17 g.

[0039] Example 3

[0040] HA@NS was prepared according to the method of Example 1, except that: in step (2), the amount of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide used was 0.48 g, and the reaction time was 2 h; in step (3), the amount of N-hydroxysuccinimide used was 0.71 g, and the reaction time was 14 h; in step (4), the amount of bursin tripeptide used was 0.085 g.

[0041] Example 4

[0042] HA@NS was prepared according to the method of Example 1, except that: in step (2), the amount of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide used was 0.24 g, and the reaction time was 4 h; in step (3), the amount of N-hydroxysuccinimide used was 0.22 g, and the reaction time was 16 h; in step (4), the amount of bursin tripeptide used was 0.17 g.

[0043] Example 5

[0044] HA@NS was prepared according to the method of Example 1, except that: in step (2), the amount of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide used was 0.096 g, and the reaction time was 15 min; in step (3), the amount of N-hydroxysuccinimide used was 0.057 g, and the reaction time was 1 h; in step (4), the amount of bursin tripeptide used was 0.085 g.

[0045] Example 6

[0046] HA@NS was prepared according to the method of Example 1, except that: in step (2), the amount of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide used was 0.192 g, and the reaction time was 4 h; in step (3), the amount of N-hydroxysuccinimide used was 0.171 g, and the reaction time was 16 h; in step (4), the amount of bursin tripeptide used was 0.0255 g.

[0047] Table 1 Molar ratio of carboxyl group of hyaluronic acid to EDC, NHS and cystin tripeptide in each embodiment

[0048]

[0049]

[0050] Example 7 Identification of HA@NS and detection of yield

[0051] (1) Identification of HA@NS

[0052] The reaction principle in Examples 1-6 is that the carboxyl group of hyaluronic acid undergoes an amidation reaction with the amino group of bursa-tripeptide to generate a hyaluronic acid-grafted bursa-tripeptide polymer.

[0053] The reaction products prepared in Example 1-6 were identified by Fourier transform infrared spectroscopy. Figure 2 Due to the amidation reaction between the carboxyl group of hyaluronic acid and the amino group of bursa tripeptide, a hyaluronic acid-grafted bursa tripeptide polymer was generated. The characteristic peak of hyaluronic acid was red-shifted from 1605 cm -1 Move to 1632cm -1 , indicating that the hyaluronic acid was successfully grafted with the tripeptide of capsin.

[0054] (2) Detection of HA@NS yield

[0055] Establishment of HA@NS detection method: Since the histidine residues that make up the tripeptide of cystin have absorption at 230nm, hyaluronic acid has no absorption at 230nm. Figure 3 Based on this, a UV absorption method for detecting HA@NS was established.

[0056] Preparation of standard curve: Using water as solvent, prepare a 50 mg / mL solution of bursin tripeptide as standard, then dilute it to 8, 6, 4, 2, 1, 0.5 mg / mL, take 100 μL of each concentration of bursin tripeptide standard and add it to the UV detection ELISA plate, and use UV spectrophotometer to detect OD at 230 nm. 230 Value, in OD 230 The value is the vertical axis, and the concentration of cystin tripeptide is the horizontal axis. Make a standard curve ( Figure 4 ), the standard curve equation is y = 0.3353x + 0.2712, R 2 = 0.992, where x is the concentration of bursin tripeptide in mg / mL and y is the OD 230 value.

[0057] The above-mentioned ultraviolet absorption method was used to detect the loading amount of bursin tripeptide in HA@NS (hyaluronic acid grafted bursin tripeptide polymer) harvested in Examples 1 to 6. Then the yield and substitution rate of HA@NS were calculated using the following formula: yield = mass of bursin tripeptide grafted to hyaluronic acid ÷ mass of bursin tripeptide input × 100%, substitution rate = molar amount of bursin tripeptide grafted to hyaluronic acid ÷ molar amount of carboxyl groups of hyaluronic acid × 100%. HA@NS was prepared according to the methods of Examples 1 to 6. The yield and substitution rate of each method are detailed in Table 2.

[0058] Table 2 Yield and substitution rate of HA@NS prepared according to the method of Examples 1-6

[0059] Example 1 2 3 4 5 6 Yield 26% 49% 56% 98% 8% 97% Replacement rate 30% 58% 66% 92% 10% 32%

[0060] Example 8 Effect of HA@NS as an immunopotentiator on the titer of neutralizing antibodies

[0061] The inactivated porcine epidemic diarrhea virus PEDV-NJ strain virus liquid (virus titer 10 7.0 TCID 50 / mL, disclosed in Chinese patent No. ZL201611248419.4, deposit number: CGMCCNO.13283) and 1313 adjuvant (purchased from SEPPIC, France) were mixed in a volume ratio of 1:1, and emulsified with an emulsifier to obtain vaccine C1.

[0062] Weigh the HA@NS freeze-dried products prepared in Examples 1 to 6 and dissolve them in inactivated porcine epidemic diarrhea virus PEDV-NJ strain virus solution (virus titer is 10 7.0 TCID 50 / mL), the concentration of HA@NS was made to be 0.05 mg / mL, and then it was mixed with 1313 adjuvant in a volume ratio of 1:1, and emulsified with an emulsifier to obtain vaccines I (containing HA@NS prepared in Example 1), II (containing HA@NS prepared in Example 2), III (containing HA@NS prepared in Example 3), IV (containing HA@NS prepared in Example 4), V (containing HA@NS prepared in Example 5) and VI (containing HA@NS prepared in Example 6).

[0063] Weigh hyaluronic acid and bursa tripeptide powders respectively and dissolve them in inactivated porcine epidemic diarrhea virus PEDV-NJ strain virus solution (virus titer is 10 7.0 TCID 50 / mL), the final concentration of hyaluronic acid and bursa-tripeptide was made to be 0.05 mg / mL, and then it was mixed with 1313 adjuvant at a volume ratio of 1:1, and emulsified with an emulsifier to obtain vaccine C2.

[0064] 80 clean-grade ICR female mice were randomly divided into 8 groups, 10 mice in each group, and subcutaneously immunized with the vaccine prepared by the above method. The immunization volume was 100 μL / mouse. Blood was collected 28 days after immunization, serum was separated, and the neutralizing antibody titer was determined. The specific method was as follows: PEDV-NJ strain virus liquid was diluted to 2000TCID using DMEM culture medium 50 / mL, dilute the serum to be tested with DMEM culture medium containing 2% calf serum at the following dilutions: 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, then take the gradient dilution serum to be tested and the diluted virus solution and mix them in equal volumes, and incubate at 37°C for 1 hour. The incubated mixture was added to a 96-well plate with Vero cells (5×10 5 Each sample was repeated 6 times, and the neutralization titer of the serum was calculated after 72 hours. Figure 5It can be seen that HA@NS can significantly increase the level of neutralizing antibodies as an immune enhancer. When the substitution rate is 30% and 32%, it has a strong immune enhancement effect. The neutralization titer of vaccines I and VI after immunization is more than 8 times that of vaccine C2 and more than 2 times that of vaccine II.

[0065] Example 9 Effect of HA@NS as an immunopotentiator on the activation levels of T cells and B cells

[0066] As an immunopotentiator, the immunopotentiating ability of HA@NS can also be evaluated by the activation levels of follicular helper T cells (TFH) and germinal center B cells (GC B cells) in the draining lymph nodes.

[0067] Vaccine VI, vaccine C1 and vaccine C2 were prepared according to Example 6. Fifteen clean-grade ICR female mice were randomly divided into three groups, each with five mice, and subcutaneously immunized with the above vaccine. The immunization volume was 100 μL / mouse. 14 days after immunization, three mice were taken from each group and killed by cervical dislocation. They were immediately disinfected with alcohol, and the inguinal lymph nodes on both sides were taken out. Lymphocytes were separated using a 200-mesh sieve, and 1×10 6 The cells were stained separately, and flow cytometry antibodies anti-CXCR5 PE, anti-Bcl-6 FITC, and anti-Vio770 / CD4 PE (purchased from Shanghai Union Biotech Co., Ltd.) were used to label TFH; anti-220FITC, anti-GL-7PE, and anti-CD38 APC (purchased from Shanghai Union Biotech Co., Ltd.) were used to label B cells (B220+) and GC B cells (B220 + GL-7 + CD38 - ), and finally flow cytometry analysis was performed. Figure 6 As shown, TFH accounted for CD4 + The proportion of T cells was also significantly higher than that of mice in vaccine C1 and vaccine C2 groups, exceeding 2.5 times that of vaccine C2 group, and the proportion of GC B cells to total B cells in the inguinal lymph nodes of vaccine group VI mice was significantly higher than that of mice in vaccine C1 and vaccine C2 groups, almost 3 times that of vaccine C2 group. Therefore, hyaluronic acid-grafted bursa-binding tripeptide polymer can enter the inguinal lymph nodes more effectively, promote the differentiation of TFH cells, assist in the screening of B cells that secrete high-affinity immunoglobulins, induce them to transform into plasma cells, and secrete high levels of antibodies.

Claims

1. A hyaluronic acid grafted bursa-tripeptide polymer, which is formed by connecting hyaluronic acid and bursa-tripeptide through an amide bond.

2. The method for preparing the hyaluronic acid-grafted cystin tripeptide polymer according to claim 1, characterized in that The steps include: (1) reacting hyaluronic acid and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide under stirring; (2) adding N-hydroxysuccinimide to the solution obtained after the reaction in step (1), and reacting under stirring; (3) Adding the bursa-tripeptide to the solution obtained after the reaction in step (2), and reacting under stirring conditions to obtain a hyaluronic acid-grafted bursa-tripeptide polymer.

3. The preparation method according to claim 2, characterized in that In step (1), hyaluronic acid is dissolved in an aqueous solvent, and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide is added to react; the aqueous solvent is a buffer solution with a pH of 5.5-7; and the mass percentage concentration of hyaluronic acid in the aqueous solvent is 0.01% to 10%.

4. The preparation method according to claim 3, characterized in that The average molecular weight of hyaluronic acid is 20-200 kDa, preferably 40-60 kDa.

5. The preparation method according to claim 4, characterized in that In step (1), the molar ratio of the carboxyl group in the hyaluronic acid to 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide is 1:1-10, preferably 1:3-5; and the reaction time is 15 min-6 h, preferably 1-3 h.

6. The preparation method according to claim 5, characterized in that The molar ratio of the carboxyl group in the hyaluronic acid to N-hydroxysuccinimide is 1:1-10, preferably 1:4-7; the reaction time in step (2) is 1-24 hours, preferably 2-18 hours.

7. The preparation method according to claim 6, characterized in that The molar ratio of the carboxyl group in hyaluronic acid to the thiourea tripeptide is 1:0.1 to 1:8, preferably 1:0.3-2; the reaction in step (3) is carried out in a buffer solution with a pH of 5 to 10, preferably a pH of 7 to 7.5; the reaction time in step (3) is 12 to 48 hours, preferably 14 to 18 hours.

8. The preparation method according to claim 7, characterized in that After the reaction in step (3) is completed, dialysis, concentration and freeze-drying are performed.

9. Use of the hyaluronic acid grafted cystin tripeptide polymer according to claim 8 as a vaccine enhancer.

10. The use according to claim 9, characterized in that The hyaluronic acid-grafted cystin tripeptide polymer is dissolved in an antigen solution, and then mixed with 1313 adjuvant at a volume ratio of 1:0.8-1.2, and emulsified to obtain an inactivated vaccine.

Citation Information

Patent Citations

  • PEDV (porcine epidemic diarrhea virus), inactivated vaccine and preparation method of inactivated vaccine

    CN106591244A